Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.58 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 3/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778588 | 0.96 | TOP1 (0.58) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL5781260 | 0.91 | TOP1 (0.52) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL6475561 | 0.90 | TOP1 (0.51) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL6483946 | 0.90 | TOP1 (0.50) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL7810923 | 0.88 | TOP1 (0.74) | TOP1KAT2BCSNK2A1TERTRAD52 | |
| SCHEMBL5781264 | 0.88 | TOP1 (0.58) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL6482851 | 0.88 | TOP1 (0.48) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL5777704 | 0.87 | TOP1 (0.56) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL5784467 | 0.87 | TOP1 (0.47) | TOP1KAT2BCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL5785230 | 0.86 | TOP1 (0.78) | TOP1CSNK2A1CSNK2A2CSNK2BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436293-B1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1436293-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | claimed |
| US-6680326-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2004-01-20 | — | — | US | claimed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | claimed |
| EP-1436293-B1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| EP-1436293-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6680326-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073691-A1 | Polycyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 | TOP1 10/4885KAT2B 670/4885CSNK2A1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.